{
  "id": 19179710,
  "title": "Argenx to buy peptide platform in potentially billion-dollar deal",
  "url": "https://urgent.news/2026/11/09/argenx-to-buy-peptide-platform-in-potentially-billion-dollar-deal",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-09T16:27:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/argenx-unnatural-products-acquisition-deal-peptides-protein-macrocyclic-immune/874119/"
  },
  "original_language": "en",
  "account": null,
  "summary": "For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}